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Three thioamide-substituted imidazoquinolinone, which possess a heterocyclic center similar to tryptanthrin and are named C1,
C2, and C3, were studied regarding (a) their in vitro anti-Trypanosoma cruzi activity, (b) their cytotoxicity and electrochemical
behaviour, and (c) their effect on cell viability, redox state, andmitochondrial function.The assayed compounds showed a significant
activity against the proliferative forms, but onlyC1 showed activity on the trypomastigote form (forC1, IC
50 epi = 1.49 𝜇M; IC50 amas =
1.74 𝜇M; and IC
50 try = 34.89 𝜇M). The presence of an antioxidant compound such as ascorbic acid or dithiotreitol induced a
threefold increase in the antiparasitic activity, whereas glutathione had a dual effect depending on its concentration. Our results
indicate that these compounds, which exhibited low toxicity to the host cells, can be reduced inside the parasite bymeans of the pool
of lowmolecular weight thiols, causing oxidative stress and parasite death by apoptosis.The antiparasitic activity of the compounds
studied could be explained by a loss of the capacity of the antioxidant defense system of the parasite to keep its intracellular redox
state. C1 could be considered a good candidate for in vivo evaluation.
1. Introduction
Chagas’ disease is endemic in Latin America, directly affect-
ing around 20 million of inhabitants, but it is also to be taken
in account that more than 200 million are at risk of infection
[1]. Trypanosoma cruzi is the etiological agent of this illness,
a hemoflagellate parasite whose life cycle involves the oblig-
atory passage through both vertebrate and invertebrate hosts
(hematophagous triatomine bugs). Currently, only two drugs
were commercially available for its treatment: Benznidazole
(Bnz) and Nifurtimox (Nfx); however, the latter has been dis-
continued. Both drugs can reduce serological titters in acute
and early chronic infections by eliminating patent para-
sitemia. Nevertheless, these drugs are not active against all T.
cruzi strains and are known to produce toxic effects on the
host [2]. All of these facts highlight the urgent need for
the development of new, cheap, safe, and more efficient
compounds for treating Chagas’ disease.
A variety of natural products are known to have antitry-
panosomal activity. Tryptanthrin (indolo[2,1-b]quinazoline-
6,12-dione) is a weak basic alkaloid isolated from medicinal
plants, such as Polygonum tinctorium, Isatis indigotica, and
Strobilanthes cusia [3]. This alkaloid has a broad spectrum of
biological functions, including anti-inflammatory,antifungal,
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Figure 1: Tryptanthrin and structurally related compounds. (A) Tryptanthrin. (B) heterocycle precursor. (C) C-10 thioamide-substituted
compounds, denominated C1 (R:H), C2 (R: Cl), and C3 (R: CH
3
). (D) C-10 amide-substituted compound.
antibacterial, and antitumor effects [4] and its references.
In addition, tryptanthrin derivatives have been shown to
possess activity against several protozoan pathogens. Specifi-
cally, these compounds have been reported to inhibit some
strains of Leishmania spp. [5, 6], Trypanosoma brucei [7],
Plasmodium falciparum [8], and Toxoplasma gondii [9].
Closely related to the tryptanthrin structure (Figure 1(A)), we
have synthesized the 2,3-dihydroimidazo[1,2-b]isoquinolin-
5(1-H)-one molecule, which is a heterocycle precursor
(Figure 1(B)) to then obtain new N-1 or C-10 substi-
tuted imidazoquinolinones derivatives, similar to tryptan-
thrin [10, 11]. Importantly, when a computational analysis
was run over, comparing tryptanthrin and the heterocy-
cle precursor structures, which consist in the overlapped
structures (HyperChem software, Hypercube. Inc), a signif-
icantly great similarity was found (root-mean-square devi-
ation, RMSD 1.69 × 10−3 A˚; unpublished data). Recalling
that thioamide derivatives substituted in C-10 (Figure 1(C))
exhibited the best antichagasic activity on T. cruzi epi-
mastigotes [11], we have therefore selected the compounds
of the C series (C1, C2, and C3, Figure 1), which showed
superior activity to that of Nfx, to study their effect in
vitro against the different stages of the parasite. D was used
as a non-C-10 thioamide substituted imidazoquinolinone
derivative (Figure 1(D)). The mechanism of action of the C
compounds was also investigated. In case that C compounds
were efficient antichagasic agents, it is worth to emphasize
that they present the additional advantages over tryptanthrin
and its derivatives of being obtained more cheaply, simply,
and efficiently.
2. Materials and Methods
2.1. Chemicals. Bnz was kindly provided by Roche
(Argentina). The compounds assayed (Figure 1) N-phenyl-5-
oxo-1,2,3,5-tetrahydroimidazo[1,2-b]isoquinolin-10-carboth-
ioamide (C1), N-(4-chlorophenyl)-5-oxo-1,2,3,5-tetra-
hydroimidazo[1,2-b]isoquinolin-10-carbothioamide (C2),
N-(4-methylphenyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-b]iso-
quinolin-10-carbothioamide (C3), and 5-oxo-N-phenyl-
1,2,3,5-tetrahydroimidazo[1,2-b]isoquinolin-10-carboxamide
(D) were synthesized according to Bollini et al. [11]. Standard
solutions of these compounds were prepared in dimethyl
sulphoxide (DMSO), and their final concentrations in the
experiments never exceeded 0.5%.
2.2. Parasites. Trypanosoma cruzi epimastigotes (Tulahuen
strain) were grown as previously described [12]. Blood-
stream trypomastigotes were obtained from infected CF1
mice by cardiac puncture. Tulahuen strain expressing the
𝛽-galactosidase gene was kindly provided by Dr Buckner
(University of Washington, USA) [13].
2.3. Animals. Inbred CF1 male mice were nursed at Facultad
de Medicina, Universidad de Buenos Aires. Animals were
handled in accordance with the guidelines established by the
Animal Care and Use Committee of the Argentine Associa-
tion of Specialists in Laboratory Animals (AADEALC).
2.4. In Vitro Assays for Anti-T. cruzi Activity. To evaluate
the growth inhibition of epimastigotes, 1.5 × 106 parasites/mL
were cultivated with different concentrations of the com-
pounds (0.50 to 15𝜇M)or Bnz (2.50 to 15𝜇M) for 4 days. Cells
growth was assessed by counting the number of cells per mL
of culture using a Neubauer chamber and was expressed as
cellular density (CD). The percentage of inhibition (%𝐼) was
calculated as %𝐼 = {1− [(CD4t −CD0)/(CD4c −CD0)]} × 100,
where the different CDs represent the cellular density of CD4t,
treated parasites on day 4; CD
0
, parasites on day 0; and CD4c,
untreated parasites (control) on day 4.
The trypanocidal effects of C1, C2, C3, D and Bnz were
also tested on bloodstream trypomastigotes according to a
standardWHOprotocol slightlymodified [14]. Briefly,mouse
blood containing trypomastigotes was treated with different
concentrations of each compound (0.30 to 350 𝜇M) or Bnz
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(0.38 to 38 𝜇M). Plates were incubated for 24 h, and surviving
parasites were counted in a Neubauer chamber as previously
described [15]. Results were expressed as the percentage of
lysed parasites (%𝐿) relative to the number of parasites in the
control: %𝐿 = [1 − (CDt/(CDc)] × 100, where CDt and CDc
represent the cellular density of treated and untreated para-
sites, respectively.
For analysis of amastigotes, J774 cells were infected with
bloodstream trypomastigotes expressing the 𝛽-galactosidase
gene at a parasite: cell ratio of 10 : 1. After 24 h, cell cultures
were washed and each compound (2 to 100 𝜇M) was added
in fresh RPMI medium without phenol red (to avoid inter-
ference with absorbance readings at 570 nm). After 7 days,
the assay was developed as described [15]. The galactosidase
activity was quantified using CPRG as substrate and measur-
ing absorbance at 570 nm in a Microplate Reader (Bio-Rad
Laboratories). Since the assayed compounds are coloured,
blanks including uninfected cells with different doses of each
compoundwere performed.The percentage of inhibition was
calculated as%𝐼 = {1−[(𝐴 it−𝐴nit)/(𝐴 ic−𝐴nic)]}×100, where
𝐴 represents the mean 𝐴
570
value recorded for 𝐴 it, treated
infected cells; 𝐴nit, treated noninfected cells; 𝐴 ic, untreated
infected cells; and 𝐴nic, untreated noninfected cells.
2.5. Cytotoxicity Assay. Vero cells were cultivated with differ-
ent concentrations of each compound (12.5–100.0 𝜇M)or Bnz
(3.0–3000𝜇M). After 48 h of incubation, cells were washed
and viability was measured by the MTT assay as previously
described [15].The selectivity index (SI) was calculated as the
50% cytotoxic concentration (CC
50
) obtained with Vero cells
divided by the 50% inhibitory concentration (IC
50
) obtained
with T. cruzi.
2.6. Electrochemical Behaviour of Thioamide-Substituted Imi-
dazoquinolinones. Cyclic voltammograms forC1,C2, andC3
dissolved in 1% DMSO were carried out using an EQMAT
instrument with an EQSOFT Processor, at a sweep rate of
0.2 V/s under a nitrogen atmosphere at room temperature,
employing lithium perchlorate as supporting electrolyte. A
three-electrode cell was used equippedwith a vitreous carbon
as working electrode, a gold wire as auxiliary electrode, and a
saturated calomel as reference electrode.
2.7. Biochemical Assays to Characterize the Antitrypanosomal
Action. Epimastigotes of T. cruzi from a 4 days culture were
incubated with C1 (7.5–22.5𝜇M) during 5–36 hours. Cells
were harvested, washed and then the following biochemical
assays were carried out.
2.7.1. Evaluation of Oxidative Stress
(a) Assay of Intracellular Oxidative Activity. The intracellular
oxidative activity was assessed by flow cytometry using the
oxidant-sensitive fluorescent probe H
2
DCFDA. As a positive
control cells were treated with 0.1mM H
2
O
2
. Stained cells
were then analyzed by a FACSCalibur flow cytometer (Becton
Dickinson) with an excitation wavelength of 480 nm and
an emission wavelength of 530 nm. Flow cytometry results
were expressed by the ratio Gmt/Gmc, where Gmt and Gmc
correspond to the geometricmean of histograms obtained for
treated and untreated cells, respectively.
(b) Determination of Antioxidant Enzymes Activity.The activ-
ities of superoxide dismutase (SOD), ascorbate peroxidase
(APx), and trypanothione reductase (TryR) were assayed as
previously established [15].
Protein concentration was determined according to the
method described by Lowry et al. [16].These values were used
to express the specific enzymatic activities as activity per mg
of protein.
(c) Determination of TotalThiol Groups.The thiol groups con-
tent was determined employing the chromogenic compound
5,5󸀠-dithiobis-2-nitrobenzoate (DTNB), as already described
[12].
2.7.2. Evaluation of Parasite Death. Cell viability and phos-
phatidylserine (PS) exposure on the parasite surface were
assessed by propidium iodide (PI) andAnnexinV-fluorescein
isothiocyanate (FITC) staining, according to the manufac-
turer’s instructions (Invitrogen). Epimastigotes exposed to
30% fresh human serum for 2 h at 28∘C were used as positive
control. Parasites were analysed by flow cytometry acquiring
20,000 events per sample.
2.7.3. Evaluation of Mitochondrial Damage. Mitochondrial
membrane potential was assessed using two well-established
assays: 3,3󸀠-dihexyloxacarbocyanine iodide (DiOC
6
) staining
and the cytochrome c release.
For the DiOC
6
assay, epimastigotes (106) were permeabi-
lized for 20min at room temperature with 0.01% saponin,
washed, and incubatedwith 30 nMDiOC
6
for 30min at 37∘C.
The positive control was done with 250 nM trifluoromethoxy
carbonyl cyanide phenyl hydrazone (FCCP) as depolarizing
agent. Stained cells were analyzed by flow cytometry with an
excitation wavelength of 484 nm and an emission wavelength
of 511 nm.
To evaluate the cytochrome c release, parasites (3 × 108)
were resuspended in PBS containing 200𝜇g/mL digitonin,
incubated on ice for 15min and then centrifuged at 9 000×g
for 10min at 4∘C. Both, mitochondrial-rich fraction (pellet,
resuspended in 50 𝜇L of PBS) and cytosolic fraction (150 𝜇L)
were subjected to Western-blot analysis for cytochrome c.
Protein extracts (10 𝜇L and 30 𝜇L of mitochondrial and
cytosolic fractions, resp.) were resolved by 14% SDS/PAGE,
transferred to nitrocellulose membranes, blocked with 3%
skimmed milk in PBS, and then incubated with specific anti-
bodies, according to the protocol of Piacenza et al. [17].
Relative intensities of bands were quantified by densitometry
using Scion Image software (Scion). Results were expressed
in arbitrary units.
2.8. Statistical Analysis. The results presented are represen-
tative of three to four separate experiments, performed in
duplicates or triplicates. All data are expressed as means ±
standard errors of the mean (SEM). To calculate the IC
50
values, the %𝐼 or %𝐿 values were plotted against the log
of drug concentration (𝜇M) and fitted with a straight line
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Table 1: Values of IC50 for the activity of the imidazoquinolinones on epi-, trypo-, and amastigotes forms of Trypanosoma cruzi.
Compound Epimastigotes Trypomastigotes Amastigotes
IC50 (𝜇M) SI IC50 (𝜇M) SI IC50 (𝜇M) SI
C1 1.49 ± 0.28 >67.1 34.89 ± 1.20 >2.9 1.74 ± 0.30 >57.5
C2 5.57 ± 0.53 >18.0 306 ± 15 >0.3 3.63 ± 0.51 >27.5
C3 1.50 ± 0.30 >66.7 246 ± 18 >0.4 1.50 ± 0.32 >66.7
D >25 ND ≫300 ND 11.44 ± 1.21 ND
Bnz 5.49 ± 0.89 15.1 30.26 ± 2.85 2.7 ND ND
IC50 and SI values were calculated as indicated in Section 2. ND: not determined.
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Figure 2: Cyclic voltammograms of C1. Profiles corresponding to: (A) different concentrations of drug in 1% DMSO: (a) 0.014𝜇M; (b)
0.14 𝜇M; (c) 0.28 𝜇M; and (d) 0.90 𝜇M. (B) (a) C1; (b) GSH: C1 (1 : 1); and (c) GSH: C1 (2 : 1). Experimental conditions were as described in
Section 2.
determined by a linear regression (Sigma Plot 10 software).
The significance of differences was evaluated using Student’
𝑡 test, taking a 𝑃 < 0.05 as significant. Flow cytometry data
were analyzed employing the WinMDI 2.9 software.
3. Results
3.1. InVitroAntitrypanosomalActivity. Results for the in vitro
assays against the different stages of the parasite are shown
in Table 1. Even though the three compounds of the series C
were found to be active, with very similar IC
50
values for epi-
and amastigotes, on trypomastigotes C1 was 10 times more
active than C2 and C3. All the tested compounds showed the
lowest in vitro trypanocidal activity when evaluated on the
trypomastigote forms. Comparing the values obtained for C
compounds and D (C-10 amide substituted analogue) it can
be concluded that the thioamide group is essential for drugs
to have a considerable anti-T. cruzi activity. Because of these
findings, C1 was selected as the most active compound of the
C series, rendering the highest antiparasitic activity against
the three stages of T. cruzi. Notably, although IC
50
of C1 and
Bnz were similar on trypomastigote stage, C1 was found to
be 3.5 times more active than Bnz on the epimastigote form
(Table 1).
3.2. Cytotoxicity Assay. Unlike Bnz, which displayed a CC
50
of 82.79 ± 2.75 𝜇M, none of the compounds evaluated were
cytotoxic at any of the concentration assayed (12.5–100.0𝜇M).
Since all the compounds displayed a CC
50
greater than
100.0 𝜇M, then the highest SI was obtained for drugs that
had the lowest IC
50
value (Table 1). C1 was the compound
presenting good SI values for the three stages.
3.3. Electrochemical Behaviour. Cyclic voltammetry is a
methodology extensively used to determinate redox proper-
ties of molecules in solution. Figure 2(A) shows the cyclic
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Figure 3: Effect of DTT, ascorbic acid and GSH on the anti-T. cruzi activity of C1. Experimental conditions were as described in Section 2.
The concentrations of C1 tested were from 1 up to 2.5 𝜇M. The value 0% of inhibition corresponds to parasites cultured in the absence of
both C1 and antioxidant compound. ∗No significant differences (𝑃 > 0.05) were found when compared to the control (0𝜇M antioxidant
compound) as assessed by Student’ 𝑡 test.
voltammograms for increasing amounts of compound C1 in
1% DMSO. A cathodic peak at −1.04V and an anodic peak
at 0.78V, corresponding to irreversible reactions of reduction
and oxidation, respectively, were observed. A very good
linear correlation between the cathodic peak current (𝑖cp)
and concentration of C1 from 0.014 to 0.28mM was ob-
served (graphic not shown). For higher drug concentrations
(0.90mM) the saturation of the electrode was evident. A
similar behaviour was obtained for the other two compounds
of theC series (data not shown). Neither the cathodic nor the
anodic peaks were measurable for the heterocycle precursor
(Figure 1(B)) when subjected to the same potentials as C1.
The electrochemical properties of C1 in the presence of a
biologically relevant thiol, glutathione (GSH), were also stud-
ied. Figure 2(B) shows the typical cycle voltammograms of
C1 in the absence and in the presence of increasing amounts
of GSH. When GSH was added at the ratio GSH :C1 (1 : 1) it
produced a significant increase in the current of both anodic
and cathodic peaks with a concomitant displacement of the
cathodic peak to low potentials. At the ratio GSH :C1 (2 : 1)
only the cathodic peak was increased, whereas the anodic
peak was the same as that obtained with the 1 : 1 ratio. The
GSH signals, at the studied concentrations, did not interfere
with the signals of C1. The electrochemical profile obtained
by adding GSH suggests that new electroactive entities
(oxidation and reduction products) had been generated. The
presence of a adduct C1-GSH was supported by the remark-
able increase in the cathodic peak current with a concomitant
displacement to lower potentials.
To obtain additional information regarding the mecha-
nism of action of C compounds, the effect of antioxidant
agents, such as dithiothreitol (DTT), ascorbic acid, and
GSH on in vitro anti-T. cruzi activity of C1 was evaluated
(Figure 3). At the concentrations tested both DTT and ascor-
bic acid considerably enhanced the inhibitory action of the
drug. Higher concentrations of these antioxidants were not
tested because in vitro they showed significant antiparasitic
activity per se. For GSH, a dual effect was observed; this
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Table 2: Effect of treatment with C1 on antioxidant enzymes activities.
Time of treatment (hours) Drug (𝜇M) SOD activity (%) APx activity (%) TryR activity (%)
5
0 100.00 ± 3.60 100.00 ± 3.89 100.00 ± 4.56
7.5 95.85 ± 2.50 111.26 ± 7.60 152.23 ± 6.38∗
15.0 99.31 ± 4.30 98.31 ± 2.10 177.17 ± 15.56∗
22.5 90.09 ± 2.30 105.20 ± 6.20 143.89 ± 4.80∗
12
0 100.00 ± 4.20 100.00 ± 1.50 100.00 ± 8.30
7.5 99.75 ± 2.90 98.30 ± 2.30 188.60 ± 12.30∗
15.0 103.92 ± 4.30 95.91 ± 4.10 251.62 ± 15.56∗
22.5 88.48 ± 3.20∗ 93.48 ± 6.20 190.55 ± 14.29∗
24
0 100.00 ± 4.50 100.00 ± 4.22 100.00 ± 6.30
7.5 98.74 ± 7.30 108.35 ± 9.20 165.23 ± 9.80∗
15.0 89.78 ± 3.50∗ 105.30 ± 6.56 198.27 ± 9.30∗
22.5 78.27 ± 4.20∗ 96.25 ± 5.80 163.56 ± 7.60∗
Experimental conditions were as described in Section 2. For each time of treatment the activity value obtained in the absence of C1 was considered as the
control value (100%). ∗Significant differences (𝑃 > 0.05) were found when compared to the control as assessed by Student’ t test.
compound was able to either enhance or inhibit the effect
of C1, depending on the concentration employed. GSH
concentrations up to 2.5𝜇M potentiated the effect of low
concentrations of C1 (no greater than 1.5 𝜇M), whereas the
effect of C1 concentrations above 1.5𝜇M was diminished. At
a concentration of GSH of 5𝜇M the inhibitory effect of C1
was completely abrogated.
3.4. Biochemical Assays to Characterize the Antitrypanosomal
Action
3.4.1. Evaluation of Oxidative Stress. For this study, epi-
mastigotes are cultured in the presence of high concentra-
tions of C1 (7.5, 15, and 22.5𝜇M) during short times of expo-
sure (5, 12, and 24 h). These concentrations and times were
selected because they were suitable for the parasite to mani-
fest a response but without causing its death nor/or allowing
it to revert such response. According to their electrochemical
properties, we expected that C1 would act as an electrophilic
compound able to generate oxidative stress inside the par-
asite. The fluorescence of H
2
DCFDA-loaded epimastigotes
was not significantly modified by C1 treatment. Thus, the
ratioGmt/Gmc was around 1 independently onC1 concentra-
tion and the time of exposure (data not shown). For the same
treatment conditions, the activities of SOD andAPx (Table 2)
were not significantly different from those obtained with the
control (only for SOD at longer times and high drug concen-
trations a slight decline in activity was observed), whereas
TryR activity values showed a significant increase for all
concentrations of C1 and all exposure times tested (Table 2).
Simultaneously, the level of low molecular mass thiols was
found to remain constant for all C1 concentrations tested,
at exposition times of 5 and 12 h (data not shown). After 24 h
of incubation a slight decrease (not more than 20%) was only
observed for the highest concentration of the drug (22.5𝜇M).
This behaviour, similar to that showed with SOD activity,
would indicate that the deleterious action of 22.5𝜇M C1
begins to be evident within 24 h of treatment. The constant
level of thiols was not surprising due to the high activity of
TryR.
3.4.2. Evaluation of Cell Death and Mitochondrial Damage.
For these assays, parasites treated with C1 at 22.5𝜇M for 8,
24, and 36 h were used. These experimental conditions were
known to lead to parasite death. Annexin-V FITC/PI staining
was used as a parameter to detect apoptotic cells. Results
demonstrated that the number of apoptotic cells increased
during the treatment with C1 in a time-dependent manner
(Figure 4(a)). The most significant differences in the levels
of apoptotic cells were observed for early apoptotic cells for
which values of 0.8%, 8.7%, and 51.0% were obtained for 0,
24, and 36 h of treatment, respectively. The number of late
apoptotic cells also increased with time of treatment but in a
less marked and significantmanner, obtaining values of 2.8%,
4.9% and 7.7% for 0, 24, and 36 h of treatment, respectively.
The number of viable nonapoptotic cells reached values of
84.8% and 40.4% for 24 and 36 h of incubation, respectively,
versus 95.9% for control (0 h).
Simultaneously, the mitochondrial membrane depolar-
ization which was evident after 24 h of treatment remained
at similar levels up to 36 h (Figure 4(b)). Depolarized cells
reached values of 77% and 84% of the evaluated cells after 24
and 36 h of treatment, respectively, versus 31% for the control
(0 h). Given that the depolarization of the outer mitochon-
drial membrane causes the release of cytochrome c into the
cytoplasm, then, the presence of cytochrome c in both mito-
chondrial and cytosolic fractions was assessed (Figure 4(c)).
Cytochrome c was detected in the parasite cytosol after 24 h
of treatment with C1 increasing up to 2.5–3 times at 36 h.
Densitometric analysis of the immunoblots showed that the
total cytochrome c (mitochondrial + released into cytosol)
inC1-treated parasites remained constant (themitochondrial
fraction of parasites nontreated was considered as control).
4. Discussion
In this work we have studied, on all stages of Trypanosoma
cruzi, the trypanosomal activity of three totally synthetic C-10
thioamide substituted imidazoquinolinones, named C1, C2,
andC3 (Figure 1(C)). As illustrated in Table 1, the three com-
pounds showed a considerable activity against epimastigotes
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and amastigotes, whereasC1 (selected as the best antichagasic
compound) was the only one displaying an activity value
similar to that obtained with Bnz for the infective form. The
high IC
50
values observed for all tested imidazoquinolinones
on trypomastigotes could be due to drug instability in pres-
ence of whole blood and/or to their association with serum
components. Only tested on epimastigotes, the heterocycle
precursor did not show antichagasic activity (IC
50
higher
than 25𝜇M, data not shown). This result together with those
obtained for compounds C on epimastigotes (Table 1) are
consistent with slight differences due to the differentmethod-
ology used, to the values previously reported by Bollini et al.
[11]. The derivatives showed activities between 5 (for C2)
to 25 (for C1 and C3) times greater than the heterocyclic
precursor. Regarding this, the heterocycle precursor and C
series compounds show on T. cruzi a behaviour similar to
tryptanthrin and its derivatives on T. brucei where the most
potent derivative had a 50% effective concentration more
than 25 times lower than that of tryptanthrin [11].
From the electrochemical study we would conclude that
the reduction of C compounds (cathodic peak near −1.04V)
could take place in vivo. The absence of the correspondent
anodic peak would indicate that this electronic transfer pro-
cess is irreversible. The anodic scans showed a peak at 0.78V
that would correspond to an irreversible oxidation reaction.
Considering that no redox reactivity was measurable for the
heterocycle precursor (Figure 1(B)) when subjected to the
same potentials asC1, it can be expected that the reduction of
the thioamide group in C-10 could take place in the biological
environment and represent a key event in the mechanism
of action of these drugs. The reactions (1) and (2) shown
below could justify the presence of the two peaks mentioned
previously. Because we have found that the cathodic peak
current is directly proportional to the C1 concentrations
(Randles-Sevcik equation) then, cyclic voltammetry can be
used to quantify concentrations of compounds C between
0.014 to 0.28mM.
On the other hand, the electrochemical profile obtained
with GSH :C1 (1 : 1) suggests that new reduction (cathodic
peak) and oxidation (anodic peak) reactions have taken place.
Reactions (3) and (4) would justify the cathodic and anodic
peaks, respectively. The presence of the C1-GSH adduct was
supported by both the increase in current and the shift of the
cathodic peak to lower potentials. Reaction (4) reaches the
saturation when the ratio GSH :C1 is higher than 1 : 1,
RNH–R󸀠C=S + 2H+ + 2e− 󳨀→ RNH–R󸀠CH–SH (1)
2RNH–R󸀠CH–SH
󳨀→ RNH–R󸀠CH–S–S–HCR󸀠–HNR + 2H+ + 2e−
(2)
RNH–R󸀠CH–SH + GSH
󳨀→ Adduct [RNH–R󸀠CH–SH − (GSH)]
(3)
RNH–R󸀠CH–SH + GSH
󳨀→ RNH–R󸀠CH–S–S–G + 2H+ + 2e−
(4)
R: −C
6
H
5
(for C1). R󸀠: anion of precursor heterocycle
(Figure 1(B)).
Considering that trypanosomatids possess high levels of
low molecular mass thiols, we could expect that the reaction
(2) was not physiologically significant. Then the probable
mechanism of action of C compounds could be represented
by the reactions (1), (3), and (4). It is important to remember
that the only low molecular mass thiol of T. cruzi is not
glutathione because this parasite has significant amounts
of trypanothione (N1, N8 bis glutathionyl-spermidine), glu-
tathionylspermidine, and ovothiol A [18]. Therefore, GSH
would not be the only species to accomplish reactions (3)
and (4) within the parasite. Independently of the interaction
between the reduced compound and low molecular thiols,
the possibility of an interaction with essential thiols from
parasite’s proteins (as enzymes) should be considered. The
stimulatory effect of trypanosomal activity of C1 observed
by adding antioxidants such as DTT, ascorbic acid, or low
concentrations of GSH (Figure 3) would support the partic-
ipation of reaction (1) as part of the mechanism of action of
this drug. Since the presence of high concentrations of GSH
abolishes the antiparasitic effect of C1, we could postulate that
reactions (3) and (4) would be involved in the metabolism of
the drug inside the parasite. The latter reactions would block
its effect.
According to these results,C1 could act as an electrophilic
compound, and therefore it could be able of producing
oxidative stress inside the parasite. Using C1 concentrations
(7.5–22.5𝜇M) and exposure times (5–24 h) for which most
of the cells remain viable (Figure 4(a)), the intracellular
oxidative state, SOD and APx activities, and the levels of –SH
groups remained unchanged. On the other hand, the only
parameter that was significantly increased even for the lower
concentration and shorter treatment time was the activity
of TryR (Table 2). An oxidation and/or a decrease in the
levels of thiols may have occurred (according to the reactions
mentioned previously) as a consequence of the addition of
C1, but the level of –SH groups was not altered, whereas it
may be restored by the TryR.
Finally, we have found that treatment with C1 (22.5𝜇M)
at times up to 36 h produced time-dependent changes in
themitochondrial membrane potential, cytochrome c release
from mitochondria into the cytoplasm, and the exposure
of PS on the outer surface leaflet of the plasma membrane
(Figure 4). These results would suggest that C1 induces the
parasite death by apoptosis.
5. Conclusions
Our findings led us to postulate that (1) to exert their
effect, the thioamide-substituted imidazoquinolinones must
undergo reduction inside the parasite, (2) the target of these
drugs would be the pool of low molecular weight thiols, con-
sidering the principal redox buffer in the parasitic protozoa
[19], and (3) the antiparasitic activity of these drugs may
be associated with a loss of the antioxidant defense system
capacity of the parasite to keep the intracellular redox state;
however, as it has been reported for other drugs, the activity
of C compounds could also be associated with a dysfunction
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Figure 4: Effect of C1 on cell death and state of the mitochondria evaluated by flow cytometry and Western blot. Epimastigotes of T. cruzi
were treated withC1 22.5 𝜇Mduring 8, 24, and 36 h. Parasites were (a) stained by Annexin V-FITC/PI, (b) stained by DIOC
6
, or (c) incubated
with digitonin, to obtain the cytosolic and mitochondrial fractions, which were subjected to Western-blot analysis for cytochrome c. The
numbers correspond to 1: untreated cells and 2, 3, and 4: treated cells with C1 during 8, 24, and 36 h, respectively. Methodology and data
analysis were carried out as described in Section 2.
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of the onlymitochondria of these organisms (concerning this
regard, additional studies are necessary to further sustained
this proposed) mediated by the loss of mitochondrial mem-
brane potential [20]. Both stress oxidative or mitochondrial
damage finally would lead to cell death by apoptosis. These
results provide supporting evidence to test in vivo the try-
panocidal action of C1 in an animalmodel of Chagas’ disease.
Considering the low income of the population suffering from
Chagas’ disease, it is important to take in account that the
synthesis of imidazoquinolinones is highly efficient, simple,
fast, and inexpensive; moreover, final products do show good
stability.Theprevious reasons convert these compounds to an
attractive therapeutic alternative more interesting than using
tryptanthrin or its derivatives, to fight this parasitosis.
Abbreviations
Bnz: Benznidazole
APx: Ascorbate peroxidase
CPRG: Chlorophenol Red-𝛽-D-galactopyranoside
DCF: Dichlorofluorescein
H
2
DCFDA: 2󸀠,7󸀠-Dichlorodihydrofluorescein diacetate
DIOC
6
: 3,3󸀠-Dihexyloxacarbocyanine iodide
DTT: Dithiothreitol
FCCP: Trifluoromethoxy carbonyl cyanide phenyl
hydrazone
FITC: Fluorescein isothiocyanate
GSH: Reduced glutathione
PI: Propidium iodide
PS: Phosphatidylserine
ROS: Reactive oxygen species
SOD: Superoxide dismutase
TCA: Trichloroacetic acid
Try: Trypanothione
TryR: Trypanothione reductase.
Conflict of Interests
The authors declare that they have no conflict of interests.
Authors’ Contribution
Alejandra B. Ciccarelli and Fernanda M. Frank contributed
equally to this work.
Acknowledgments
The authors thank Dr. Cecilia Bonazzola, Departamento de
Quı´mica Fı´sica, Facultad de Ciencias Exactas y Naturales,
UBA, for critical reading of the paper. This work was
supported by Grants from UBA (UBACYT B001, X083, and
20020090200478) and CONICET (PIP 5263).
References
[1] E. Castillo, M. A. Dea-Ayuela, F. Bola´s-Ferna´ndez, M. Rangel,
andM. E. Gonza´lez-Rosende, “The kinetoplastid chemotherapy
revisited: current drugs, recent advances and future perspec-
tives,” Current Medicinal Chemistry, vol. 17, no. 33, pp. 4027–
4051, 2010.
[2] J. Jannin and L. Villa, “An overview of Chagas disease treat-
ment,” Memorias do Instituto Oswaldo Cruz, vol. 102, supple-
ment 1, pp. 95–97, 2007.
[3] L. A. Mitscher, W. C. Wong, T. DeMeulenaere, J. Sulko, and S.
Drake, “Antimicrobial agents from higher plants. New synthesis
and bioactivity of tryptanthrin (indolo [2, 1b]quinazolin-6, 12-
dione) and its analogs,”Heterocycles, vol. 15, pp. 1017–1018, 1981.
[4] S. Miao, X. Shi, H. Zhang et al., “Proliferation-attenuating and
apoptosis-inducing effects of tryptanthrin on human chronic
myeloid leukemia K562 cell line in vitro,” International Journal
of Molecular Sciences, vol. 12, no. 6, pp. 3831–3845, 2011.
[5] A. K. Bhattacharjee, D. J. Skanchy, B. Jennings, T. H. Hudson,
J. J. Brendle, and K. A. Werbovetz, “Analysis of stereoelec-
tronic properties, mechanism of action and pharmacophore
of synthetic indolo[2,1-b]quinazoline-6,12-dione derivatives in
relation to antileishmanial activity using quantum chemical,
cyclic voltammetry and 3-D-QSAR CATALYST procedures,”
Bioorganic and Medicinal Chemistry, vol. 10, no. 6, pp. 1979–
1989, 2002.
[6] K. M. Grant, M. H. Dunion, V. Yardley et al., “Inhibitors of
Leishmania mexicana CRK3 cyclin-dependent kinase: chemi-
cal library screen and antileishmanial activity,” Antimicrobial
Agents and Chemotherapy, vol. 48, no. 8, pp. 3033–3042, 2004.
[7] J. Scovill, E. Blank, M. Konnick, E. Nenortas, and T. Shapiro,
“Antitrypanosomal activities of tryptanthrins,” Antimicrobial
Agents and Chemotherapy, vol. 46, no. 3, pp. 882–883, 2002.
[8] A. K. Bhattacharjee, M. G. Hartell, D. A. Nichols et al.,
“Structure-activity relationship study of antimalarial indolo
[2,1-b]quinazoline-6,12-diones (tryptanthrins). Three dimen-
sional pharmacophoremodeling and identification of new anti-
malarial candidates,” European Journal of Medicinal Chemistry,
vol. 39, no. 1, pp. 59–67, 2004.
[9] B. Krivogorsky, P. Grundt, R. Yolken, and L. Jones-Brando,
“Inhibition of Leishmania mexicana by indirubin and tryptan-
thrin analogs,” Antimicrobial Agents and Chemotherapy, vol. 52,
no. 12, pp. 4466–4469, 2008.
[10] M. Bollini, S. E. As´ıs, and A. M. Bruno, “Synthesis of 2,3-
dihydroimidazo[1,2-b]isoquinoline-5(1H)-one andderivatives,”
Synthesis, no. 2, Article ID M03605SS, pp. 237–242, 2006.
[11] M. Bollini, J. J. Casal, D. E. Alvarez et al., “New potent
imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi
agents: biological evaluation and structure-activity relation-
ships,” Bioorganic and Medicinal Chemistry, vol. 17, no. 4, pp.
1437–1444, 2009.
[12] A. Ciccarelli, L. Araujo, A. Batlle, and E. Lombardo, “Effect of
haemin on growth, protein content and the antioxidant defence
system in Trypanosoma cruzi,” Parasitology, vol. 134, no. 7, pp.
959–965, 2007.
[13] F. S. Buckner, C. L. M. J. Verlinde, A. C. La Flamme, and W.
C. Van Voorhis, “Efficient technique for screening drugs for
activity against Trypanosoma cruzi using parasites expressing
𝛽-galactosidase,” Antimicrobial Agents and Chemotherapy, vol.
40, no. 11, pp. 2592–2597, 1996.
[14] M. Esteva, A. M. Ruiz, and A. M. Stoka, “Trypanosoma cruzi:
methoprene is a potent agent to sterilize blood infected with
trypomastigotes,” Experimental Parasitology, vol. 100, no. 4, pp.
248–251, 2002.
[15] A. B. Ciccarelli, F.M. Frank,V. Puente, E. L.Malchiodi, A. Batlle,
and M. E. Lombardo, “Antiparasitic effect of vitamin B
12
on
10 Evidence-Based Complementary and Alternative Medicine
Trypanosoma cruzi,” Antimicrobial Agents and Chemotherapy,
vol. 56, no. 10, pp. 5315–5320, 2012.
[16] O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall,
“Protein measurement with the Folin phenol reagent,” The
Journal of biological chemistry, vol. 193, no. 1, pp. 265–275, 1951.
[17] L. Piacenza, F. Irigoı´n, M. N. Alvarez et al., “Mitochondrial
superoxide radicals mediate programmed cell death in Try-
panosoma cruzi: cytoprotective action of mitochondrial iron
superoxide dismutase overexpression,”Biochemical Journal, vol.
403, no. 2, pp. 323–334, 2007.
[18] D. J. Steenkamp, “Thiol metabolism of the trypanosomatids as
potential drug targets,” IUBMB Life, vol. 53, no. 4-5, pp. 243–
248, 2002.
[19] S. Mu¨ller, E. Liebau, R. D. Walter, and R. L. Krauth-Siegel,
“Thiol-based redox metabolism of protozoan parasites,” Trends
in Parasitology, vol. 19, no. 7, pp. 320–328, 2003.
[20] D. Smirlis, M. Duszenko, A. J. Ruiz et al., “Targeting essential
pathways in trypanosomatids gives insights into protozoan
mechanisms of cell death,” Parasites and Vectors, vol. 3, no. 1,
pp. 107–121, 2010.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
